LSU Health New Orleans scientists say they have finally nailed down why premenopausal women with obesity who take estrogen-containing medications are far more likely to develop dangerous blood clots. The short version: when obesity and estrogen show up together, levels of protein S, a key anticoagulant made in the liver, drop sharply and clot-forming activity jumps.
That single pathway, tying a known clinical risk to a specific molecular mechanism, could eventually change how some high-risk patients are watched and treated.
The study, published in the Journal of Clinical Investigation, analyzed plasma from 157 women and used mouse and cell models. Researchers found that obesity alone or estrogen alone lowered protein S, but the combination really cranked up clotting potential, boosting thrombin generation by as much as 2.7-fold in some tests. The team reports that hypoxia-inducible factor 1α (HIF1α) latches onto the PROS1 promoter and suppresses its activity, offering a direct molecular explanation for the protein S drop. The work lists support from NIH grants, a sign of significant federal investment in the project.
Lead investigator Dr. Rinku Majumder pulled together collaborators across LSU Health New Orleans’ Department of Interdisciplinary Oncology, the Department of Genetics and the LSU LCMC Health Cancer Center, along with international partners, according to LSU Health New Orleans. The institution’s release highlights cancer patients as a group where this finding may matter most, since they already walk into treatment with elevated clotting risk. Local researchers say the mechanism they uncovered — estrogen plus obesity driving down protein S through HIF1α — hands clinicians a concrete target for monitoring and prevention.
New Orleans CityBusiness, which first spotlighted the hometown angle, reports that the team is urging clinicians to think about stepped-up monitoring or prevention for patients most at risk, including those with cancer or other prothrombotic conditions. As New Orleans CityBusiness notes, the results land squarely in the middle of real-world decisions about prescribing and counseling on estrogen-containing birth control and hormone therapies. Public-health voices say the work also throws fresh light on Louisiana’s high obesity rates as a modifiable driver of serious complications.
How obesity and estrogen converge on protein S
The team reports that obesity sets up a low-oxygen, or hypoxic, environment in the liver that stabilizes HIF1α. At the same time, estrogen signaling through estrogen receptor α further suppresses PROS1, the gene that encodes protein S. In their cell and animal models, HIF1α was shown to bind directly to the PROS1 promoter and shut down its transcription, leading to lower levels of both free and total protein S and boosting thrombin generation, according to the Journal of Clinical Investigation. That tight mechanistic story helps explain why earlier population studies kept finding that obese women on estrogen-containing contraceptives were hit with several-fold higher clot risk.
What patients should know
For now, this is a mechanistic research study, not a new rulebook. Patients are warned not to stop or change any prescribed medications without a conversation with their clinician. LSU Health advises that providers factor a patient’s obesity status into discussions about estrogen-based options and consider more individualized monitoring for those at higher risk, according to LSU Health New Orleans. People with personal or family histories of clots, those undergoing cancer treatment, or anyone stacking multiple risk factors may deserve extra attention.
What’s next
The authors say they now need larger clinical studies to connect the size of protein S reductions with actual venous thromboembolism events in real-world populations. They also want to test whether restoring protein S levels or blocking HIF1α activity can meaningfully dial down clot risk. With NIH backing and a solid base of translational mouse and cell work, the group sees a path toward more targeted strategies, from adjusting contraceptive counseling to exploring therapies that better protect high-risk patients. Local specialists expect follow-up research and trials to sharpen risk thresholds and eventually feed into formal guidelines.
